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Abstract
As noted in other flaviviruses, the envelope (E) protein of Japanese encephalitis virus (JEV) interacts
with a cellular receptor and mediates membrane fusion to allow viral entry into target cells, thus
eliciting neutralizing antibody response. The formation of the flavivirus prM/E complex is followed
by the cleavage of precursor membrane (prM) and membrane (M) protein by a cellular signalase.
To test the effect of prM in JEV biology, we constucted JEV-MuLV pseudotyped viruses that express
the prM/E protein or E only. The infectivity and titers of JEV pseudotyped viruses were examined
in several cell lines. We also analyzed the neutralizing capacities with anti-JEV sera from JEV-
immunized mice. Even though prM is crucial for multiple stages of JEV biology, the JEV-pseudotyped
viruses produced with prM/E or with E only showed similar infectivity and titers in several cell lines
and similar neutralizing sensitivity. These results showed that JEV-MuLV pseudotyped viruses did
not require prM for production of infectious pseudotyped viruses.
Findings
Japanese encephalitis virus (JEV) is a serious mosquito-
borne flavivirus that causes pandemic infectious disease
of major public health importance in Asia. JEV is a mem-
ber of the genus Flavivirus in the family Flaviviridae, which
includes yellow fever virus, Dengue virus, West Nile virus,
and St. Louis encephalitis virus [1,2].
The JEV single-stranded RNA genome (≈ 11 kb) encodes
three structural proteins – capsid (C), premembrane
(prM) or membrane (M), and envelope (E) protein – and
seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) proteins [3-5].
The assembly of JEV in the endoplasmic reticulum is fol-
lowed by modification of the two envelope proteins E and
prM and virion export through the secretory pathway.
PrM (≈ 26 kDa) is a precursor of the membrane-anchored
and it cleaved a soluble Pr peptide and virion associated
M protein (≈ 8 kDa) by trans-Golgi resident furin or
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ion: the intracellular E- and prM-containing form, and the
extracellular E- and M-containing form [3,7].
The E protein plays a major role in virus assembly, adhe-
sion, receptor binding and membrane fusion, hemagglu-
tination inhibition (HI), and induction of neutralizing
antibodies (Nabs) [8-10]. Therefore, the E protein is the
principal target of neutralization by specific antibodies
against JEV infection [4,11]. E proteins of JEV expressed in
different viral vector systems such as vaccinia virus, sind-
bis virus, and baculovirus have elicited high levels of neu-
tralizing antibodies against JEV infection and have been
tested as second generation JEV vaccines in mice [7,12-
14]. From these reports, it is unknown whether prM cleav-
age affects infectivity, E protein expression, or induction
of neutralizing activity. A major function of prM was stud-
ied by blocking prM cleavage or by mutation of the con-
served glycosylation motif of JEV prM [15]. Even though
the direct role of prM during the viral replication was not
elucidated [6], it has a crucial function in multiple stages
of JEV biology.
We generated pseudotyped viruses containing the prM/E
or E protein of the current JEV vaccine strains Nakayama-
NIH (NK) and Beijing-1 (BJ). The DNA fragments encod-
ing the E and prM/E regions were amplified by polymer-
ase chain reaction (PCR) from the cDNA of the NK strain
and BJ strain kindly supplied from the Department of Vac-
cine, KFDA, Korea. PCRs were performed using one of the
two forward primers: for prM/E amplification, 5'-AATGA-
GAATTCGACCATGTGGCTCGCAAGCTTGGC-3'; and for
E amplification, 5'-GGTCGCGAATTCTGCAGGTTCAACT-
GTCTGGGAGTG-3'. The reverse primer for both amplifi-
cations was 5'-ACCAATGTGCATGCTTAGCTCGAGAATT
CCATTG-3'. Each primer had an EcoRI restriction site. To
generate pHCMV-prM/E and pHCMV-E, the PCR products
of prM/E and E were digested with EcoRI and subse-
quently cloned into pHCMV-G [16] digested with EcoRI
(Figure 1).
Pseudotyped viruses encoding prM/E or E of JEV NK and
BJ strain were produced as previously described [17].
Briefly, TELCeB6 cells, a MuLV packaging cell line [18],
were transfected with pHCMV-E or pHCMV-prM/E by a
calcium phosphate method. After overnight incubation,
the culture medium was replaced, and the cells were incu-
bated for two additional days. The supernatants contain-
ing pseudotyped viruses were harvested by low speed
centrifugation (1,500 × g, 5 min) to remove cell debris.
Figure 2 shows the expression of the E proteins from each
pseudotyped JEV constructs by western blot analysis using
anti-JEV (Nakayama) sera. The envelope genes of the NK
and BK strains were expressed well in cell culture superna-
tants and lysates. Similar amounts of E proteins were
expressed in NK and BJ transfected cells.
The JEV-pseudotyped viruses expressing prM-E and E were
properly processed and released into the culture media
Construction of JEV pHCMV-prM/E and pHCMV-EFigure 1
Construction of JEV pHCMV-prM/E and pHCMV-E. Four plasmids were produced: pHCMV-prM/E (NK or BJ) and 
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tein bands were not detected despite many attempts. To
check the expression of the prM/Env gene during pseudo-
typed virus formation, we performed reverse transcription
(RT)-PCR. Figure 3 shows the amplified JEV prM/Env
(2062 bp), Env (1501 bp) transcripts in transfected
TELCeB6 cells. We assumed that the cleavage of the prM
protein is too rapid to detect with prM/E polyprotein and
our sera from JEV-immunized mice did not contain the
prM antibodies.
Expression of JEV envelope (E) proteinFigure 2
Expression of JEV envelope (E) protein. Cell lysate and culture media of JEV-pseudotyped viruses were subjected to SDS-
PAGE. JEV-E proteins were detected by western blotting using sera from mice immunized with JEV (Nakayama-NIH strain). 
The bands show the JEV-E protein (53 kDa) in cell lysates and culture supernatants. Non-transfected TELCeB6 cells were used 
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Expression of JEV prM and Env genes in TELCeB6 cellsFigure 3
Expression of JEV prM and Env genes in TELCeB6 cells. TELCeB6 cells were transfected with pHCMV-prM/E and 
pHCMV-E of each of NK and BJ strains. RT-PCR products of the indicated size were amplified from total RNA samples 
extracted from TELCeB6 cells. The products correspond to 2 Kb of prM (amplified by prM/E primer) and 1.5 Kb of Env (ampli-
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and viral titer, infection tests with the pseudotyped viruses
were carried out in in 96-well plates with Vero, PK15,
CRFK, NIH3T3, HeLa, 293T, BHK-21, MDCK, and HOS
cells. Four kinds of pseudotyped JEVs were added to the
host cells and incubated at 37°C in a 5% CO2 incubator
for 36 hours. All infections were done in triplicate. After X-
gal staining, JEV pseudotyped virus-infected cells
appeared blue. This resulted from integration of the MuLV
pseudovirus genome encoding β-galactosidase. These
cells were counted as an infectious unit. All JEV pseudo-
typed viruses could infect PK15, CRFK, NIH3T3, HeLa,
293T, BHK-21, Vero, and MDCK cells, but not HOS cells
(Table 1).
The titers of pseudotyped viruses were comparable to the
infectivity of JEV in each host cell line. JEV pseudotyped
virus with E or prM/E (both NK and BJ strain) could effi-
ciently infect several cell lines, with typical titers between
1.14 × 102 and 1.36 × 105 infectious units (IFU)/mL. From
Table 1, viruses pseudotyped with prM/E exhibited infec-
tivity similar to those pseudotyped with E only. This
showed that the infectivity and titer of JEV pseudotyped
virus is not affected by prM deletion.
Neutralizing sensitivity was tested with JEV-immunized
immune sera, which was supplied by the Catholic Univer-
sity of Korea, to check the effect of prM on pseudotyped
JEV antigens. As previously described [17], neutralization
assays were carried out with Vero cells in triplicate.
Approximately 100 IFU/mL of pseudotyped viruses were
incubated with 10-fold diluted sera from mice immu-
nized with JEV for 1 h at 37°C, and the mixture was sub-
sequently added to Vero cells. After 2 days of incubation,
virus infection was monitored by X-gal staining as
described above. The neutralizing sensitivity was
expressed as virus reduction by neutralizing antibodies.
Figure 4 shows the reduction of pseudotyped JEVs by neu-
tralization with homologous and heterologous sera. A
high neutralization was observed with 1:10 diluted
serum. In contrast, no neutralizing activity was detected in
the normal mouse serum (reduction was less than 30%).
The neutralization by homologous sera was more com-
plete than that by heterologous sera. However, there was
no significant difference between pseudotyped JEV prM/
Env and Env.
In summary, we generated pseudotyped JEVs that express
prM/E or E proteins from two JEV vaccine strains NK and
BJ. All four JEV pseudotyped viruses efficiently infected
several cell lines and were neutralized by sera from JEV-
immunized mice. The main purpose of generating JEV
pseudotyped virus was to devise a safe and rapid assay sys-
tem to assess neutralizing antibodies by avoiding the use
of infectious, replication-competent JEVs in a Biosafety
Level 3 laboratory. The titer of the four JEV pseudotyped
viruses was greater than 104 IFU/ml. This confirmed the
possibility of mass-producing viruses to conduct neutrali-
zation assays with Vero and CRFK cells. Even though a
crucial function of prM in assembly and maturation of fla-
viviruses has been reported, the two types of JEV-MuLV
pseudotyped virus that respectively express the E or prM/
E proteins were found to have no significant difference in
the level of transcription and the extent of protein expres-
sion, infectivity, titer, and neutralization sensitivity.
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Table 1: Infectivity and titer of JEV pseudotyped viruses in host cells
Infectious units/ml (IFU/ml)
Host cell
JEV pseudotyed virus Vero BHK-21 HeLa CRFK PK15 293T MDBK HOS
NK prM/E 4.09 *104 7.46 *103 4.08 *103 9.74 *104 1.33 *103 1.14 *102 2.08 *102 0
NK E 4.25 *104 7.58 *103 4.12 *103 1.20 *105 1.09 *103 1.32 *102 2.11 *102 0
BJ prM/E 4.12 *104 7.76 *103 4.35 *103 1.02 *105 1.82 *103 2.04 *102 2.08 *102 0
BJ E 4.83*104 7.91 *103 4.29 *103 1.36*105 2.90 *103 2.05 *102 2.23 *102 0Page 4 of 6
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